PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24524N04042024-25 FLU vaccine ORDER for the — Glaxosmithkline, LLC

Glaxosmithkline, LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36E79724D0005. PoP ended Oct 15, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

245-Network Contract Office 5 (36C245)

Awarding office

Glaxosmithkline, LLC

Recipient

Oct 15, 2024

PoP end

$108K

Obligated

$108K

Potential

325412

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline, LLC — $90

Contract facts

Federal

Contract number36C24524N0404

Also listed as36C245-24-N-0404

Also listed as36E79724D0005-36C24524N0404

Agency245-Network Contract Office 5 (36C245)

Awarding office245-Network Contract Office 5 (36C245)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentGlaxosmithkline, LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36E79724D0005

Place of performanceDURHAM NC

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMar 22, 2024

PoP end (current)Oct 15, 2024

Obligated$108K

Current value$108K

Potential value$108K

2024-25 FLU VACCINE ORDER FOR THE WASHINGTON DC VA MEDICAL CENTER. is a federal award for 245-Network Contract Office 5 (36C245) held by Glaxosmithkline, LLC. Estimated value $108K ($108K obligated). Current period of performance ends Oct 15, 2024. Place of performance: DURHAM NC.

2024-25 FLU VACCINE ORDER FOR THE WASHINGTON DC VA MEDICAL CENTER.

Recompete timing

Public

● Past PoP end (676 days ago)

Current PoP ended Oct 15, 2024 (676 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline, LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50125F61019

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E

$491K

Aug 30, 2026

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C24524N0404?

36C24524N0404 (2024-25 FLU vaccine ORDER for the) is a 245-Network Contract Office 5 (36C245) award with a potential value of $108K, currently held by Glaxosmithkline, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C245-24-N-0404?

36C245-24-N-0404 is the dashed form of PIID 36C24524N0404 (2024-25 FLU vaccine ORDER for the), held by Glaxosmithkline, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C24524N0404?

245-Network Contract Office 5 (36C245) awarded 36C24524N0404 to Glaxosmithkline, LLC (potential $108K).

Who is the incumbent on 36C24524N0404?

Glaxosmithkline, LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Oct 15, 2024.

When does Glaxosmithkline, LLC’s 36C24524N0404 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 15, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Mar 22, 2024